MedWatch

Minor biotech-success heading for patient studies

The Danish biotech company Orphazyme has received financial backing from Novo A/S through all its development phases. Next year the company is ready to take another big step forward.

The small, but well-performing, biotech company Orphazyme expects to enroll patients and initiate phase I/II studies in the late fall of 2013, and everything is going according to plan, says CSO Thomas Kirkegaard Jensen.

Even the deficit of 16.8 million kroner (3 million USD) in the newly-disclosed financial statement for 2011/12 was part of the plan. Equity was at 57.2 million kroner (9.95 million USD), while the balance was at 60.8 million kroner (10.5 million USD).

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

CHMP anbefaler coronapille fra Pfizer

Pfizer har fået en positiv anbefaling fra CHMP, der anbefaler at tabletbehandlingen Paxlovid godkendes til behandling af covid-19. I Danmark er midlet dog allerede taget i brug.

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier